A daily dose of atrasentan added to renin-angiotensin system inhibitors may slow the progression to end-stage kidney disease (ESKD) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), results from the SONAR* trial showed.
Increasing age, multiple comorbidities, and diabetic nephropathy are among the factors associated with an elevated risk of sarcopenia in ambulatory elderly patients with type 2 diabetes (T2D), according to a study from Singapore.
Supplementation with vitamin D among vitamin D-sufficient adults who are at high risk of developing diabetes does not reduce the risk of developing the disease vs placebo, according to the randomized, placebo-controlled D2d* trial.
The sodium/glucose cotransporter 2 inhibitor bexagliflozin demonstrates renoprotective potential in the management of patients with type 2 diabetes mellitus and stage 3a/3b chronic kidney disease, reducing glycated haemoglobin levels with a tolerable safety profile, according to the results of a phase III trial.
Individuals who have a spouse with diabetes are at increased risk of developing type 2 diabetes themselves, with the effect of spousal diabetes status going beyond the effect of other risk factors, according to a study.
Bariatric surgery plays a role in the treatment of obstructive sleep apnoea (OSA), inducing improvements in apnoea-hypopnea index (AHI), symptoms and consequences, although the effect appears to be greater on the last two, according to an expert who spoke at the American Thoracic Society (ATS) 2019 International Conference.
Hybrid closed-loop control (HCLC) cuts the risk and frequency of hypoglycaemia relative to sensor-augmented pump (SAP) therapy in type 1 diabetes (T1D) patients at moderate-to-high risk of hypoglycaemia, according to a recent study.
The glucagon-like peptide 1 (GLP-1) agonist liraglutide can bring sugar levels under control in children with type 2 diabetes (T2D) when added to metformin with or without basal insulin, although such benefit is gained at the expense of an increased frequency of gastrointestinal adverse events (AEs), according to the results of the phase III Ellipse Trial.
Gestational diabetes and abnormal glucose levels in pregnancy, as determined with an oral glucose challenge test (OGCT) at 24–28 weeks gestation, could signal a future risk of cardiovascular disease (CVD)*, according to a recent study.
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.